New interface greatly expands value to local users and helps to accelerate innovation in the fastest emerging market for the bio-pharmaceutical industry
PHILADELPHIA, USA. April 29, 2019 — China has become the second largest and fastest emerging market for the bio-pharmaceuticals industry, making it essential for drug developers in the region to access complex information in their native language.1 Clarivate Analytics, a global leader in providing trusted insights and analytics to accelerate the pace of innovation, today introduced a Simplified Chinese user interface for Cortellis to address this need. The Cortellis suite of life science intelligence solutions bring together data and insights on new product pipelines, deals, clinical trials and global regulatory requirements, plus predictive analytics on pipeline milestones and success rates – all now available using Simplified Chinese navigation and on-screen guidance.
The new Chinese interface serves an increasingly important market in the life sciences space. According to Cortellis, China is home to more than 1,300 biopharma companies (excluding generics companies), 218 biosimilar companies (more than any other country globally), and is considered a research hub for immuno-oncology with 153 companies using CAR-T cell therapy, second only to the U.S.
Available across the entire suite of Cortellis solutions, the interface makes research easier and more efficient. Users can easily access information in Simplified Chinese with one click, triggering automatic translation of all navigational and other interface elements.
“As the market in China continues to grow, the new Simplified Chinese user interface for Cortellis enables us to better support R&D efforts in the region, ultimately bringing life-saving drugs to market faster and more efficiently,” said Mukhtar Ahmed, President of Life Sciences at Clarivate Analytics. “This is the latest in a series of enhancements we’re introducing across the entire Cortellis portfolio, all of which are designed to enhance ease of use, provide greater value and ultimately accelerate innovation.”
Drawing on the industry’s broadest and deepest sources of competitive, regulatory and deals intelligence and analytics, Cortellis unlocks hidden insights in the data to help researchers assess the competitive landscape, understand global regulatory requirements, develop portfolio strategies, find the right partner and negotiate the best possible deal – faster and with greater accuracy compared to any other solution on the market. Currently, Cortellis curates 70,000+ pipeline products, 325,000+ clinical trials, 91,000+ deals, 165,000 company profiles, 200,000+ regulatory reference documents, and over 9 million patents worldwide.
- China Pharmaceuticals 2018, Global Business Reports
Cortellis gives life to science by unlocking the hidden insights in data. As an industry-leading solution, Cortellis curates broad and deep sources of intelligence to enable precise, actionable answers to specific questions across the R&D lifecycle — from discovery and clinical development through regulatory submission and commercialization. By supporting data-driven decisions, Cortellis helps pharmaceutical companies, biotech and medical device/diagnostic firms accelerate innovation.
For more information, visit clarivate.com/products/cortellis/.
Clarivate Analytics is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. Building on a heritage going back more than a century and a half, we have built some of the most trusted brands across the innovation lifecycle, including the Web of Science, Cortellis, Derwent, CompuMark, MarkMonitor and Techstreet. Today, Clarivate Analytics is a new and independent company on a bold entrepreneurial mission, to help our clients radically reduce the time from new ideas to life-changing innovations.
For more information, please visit clarivate.com.
This press release and oral statements made with respect to information contained in this release may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide Clarivate Analytics’ current expectations or forecasts of future events and may include statements regarding anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics’ control that may cause actual results to differ materially. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.